Securing Medical Supply Chains with Trusted Trade Partners

There is bipartisan consensus on Capitol Hill and in the Biden administration regarding excessive dependence on Chinese manufacturing and production. An extension of this is that diversification of supply chains for certain medical products will make U.S. citizens more secure in fighting future infectious diseases.

The highly disrupted international economic environment, reeling from supply and demand dislocations unleashed by the pandemic, U.S.-China trade conflicts, and war in Eastern Europe, is prompting certain countries in the Western Hemisphere to seize the occasion to aggressively market themselves as attractive hosts for foreign direct investment looking to move closer to the U.S. market. It is an opportune time for the United States to shape some of the larger forces of global economic disruption, including the movement of investment and production capital. It is time to forge enhanced trade links and diversified supply chains with friends and allies to promote health security, stronger economic and diplomatic engagement, commitments to exchange of data on production, and best practices in fighting disease. This paper breaks down CSIS’s analyses on the capacity for nearshoring in Canada, Brazil, Colombia, and Mexico.

This report was made possible by support from Pfizer Inc. and Gilead Sciences.